Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179436 · ClinicalTrials.gov registry record · Phase 1
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 415
- Enrollment target
NCT03179436 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 415 participants.
The verdict
NCT03179436, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 415 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Quavonlimab
- DRUG Pembrolizumab/Quavonlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2017-07-02 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179436
The ClinicalTrials.gov registry entry for NCT03179436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03179436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179436 about?
NCT03179436 is a clinical study titled "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)". This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
What is the current status of trial NCT03179436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 415 participants. The study started on 2017-07-02. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT03179436?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Quavonlimab (BIOLOGICAL), Pembrolizumab/Quavonlimab (DRUG).
Who is sponsoring clinical trial NCT03179436?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.